139 related articles for article (PubMed ID: 8744846)
1. Preclinical safety profile of brimonidine.
Angelov OV; Wiese AG; Tang-Liu DD; Acheampong AA; Ismail IM; Brar BS
Eur J Ophthalmol; 1996; 6(1):21-5. PubMed ID: 8744846
[TBL] [Abstract][Full Text] [Related]
2. Adrenergic and imidazoline receptor-mediated responses to UK-14,304-18 (brimonidine) in rabbits and monkeys. A species difference.
Burke J; Kharlamb A; Shan T; Runde E; Padillo E; Manlapaz C; Wheeler L
Ann N Y Acad Sci; 1995 Jul; 763():78-95. PubMed ID: 7677389
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of brimonidine.
Burke J; Schwartz M
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S9-18. PubMed ID: 8970245
[TBL] [Abstract][Full Text] [Related]
4. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2.
Schuman JS
Ophthalmology; 2000 Jun; 107(6):1171-7. PubMed ID: 10857839
[TBL] [Abstract][Full Text] [Related]
5. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
[TBL] [Abstract][Full Text] [Related]
6. Twelve-month results of an ongoing randomized trial comparing brimonidine tartrate 0.2% and timolol 0.5% given twice daily in patients with glaucoma or ocular hypertension. Brimonidine Study Group 2.
LeBlanc RP
Ophthalmology; 1998 Oct; 105(10):1960-7. PubMed ID: 9787370
[TBL] [Abstract][Full Text] [Related]
7. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies.
Walters TR
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S19-26. PubMed ID: 8970246
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of brimonidine in children with glaucoma.
Enyedi LB; Freedman SF
J AAPOS; 2001 Oct; 5(5):281-4. PubMed ID: 11641636
[TBL] [Abstract][Full Text] [Related]
9. Reversible cicatricial ectropion precipitated by topical brimonidine eye drops.
Aristodemou P; Baer R
Ophthalmic Plast Reconstr Surg; 2008; 24(1):57-8. PubMed ID: 18209648
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension.
Schuman JS
Surv Ophthalmol; 1996 Nov; 41 Suppl 1():S27-37. PubMed ID: 8970247
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the efficacy and tolerability of brimonidine and latanoprost in adults with open-angle glaucoma or ocular hypertension: a three-month, multicenter, randomized, double-masked, parallel-group trial.
DuBiner HB; Mroz M; Shapiro AM; Dirks MS;
Clin Ther; 2001 Dec; 23(12):1969-83. PubMed ID: 11813932
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents.
Maus TL; Nau C; Brubaker RF
Arch Ophthalmol; 1999 May; 117(5):586-91. PubMed ID: 10326954
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the safety and efficacy of dorzolamide 2% and brimonidine 0.2% in patients with glaucoma or ocular hypertension.
Whitson JT; Henry C; Hughes B; Lee DA; Terry S; Fechtner RD
J Glaucoma; 2004 Apr; 13(2):168-73. PubMed ID: 15097265
[TBL] [Abstract][Full Text] [Related]
14. Effects of brimonidine on aqueous humor dynamics in human eyes.
Toris CB; Gleason ML; Camras CB; Yablonski ME
Arch Ophthalmol; 1995 Dec; 113(12):1514-7. PubMed ID: 7487618
[TBL] [Abstract][Full Text] [Related]
15. Brimonidine: a new alpha2-adrenoreceptor agonist for glaucoma treatment.
Greenfield DS; Liebmann JM; Ritch R
J Glaucoma; 1997 Aug; 6(4):250-8. PubMed ID: 9264305
[TBL] [Abstract][Full Text] [Related]
16. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension. A controlled, randomized, multicenter clinical trial. Chronic Brimonidine Study Group.
Schuman JS; Horwitz B; Choplin NT; David R; Albracht D; Chen K
Arch Ophthalmol; 1997 Jul; 115(7):847-52. PubMed ID: 9230823
[TBL] [Abstract][Full Text] [Related]
17. Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathectomized monkeys.
Gabelt BT; Robinson JC; Hubbard WC; Peterson CM; Debink N; Wadhwa A; Kaufman PL
Exp Eye Res; 1994 Dec; 59(6):633-44. PubMed ID: 7698258
[TBL] [Abstract][Full Text] [Related]
18. Twelve-month evaluation of brimonidine-purite versus brimonidine in patients with glaucoma or ocular hypertension.
Katz LJ
J Glaucoma; 2002 Apr; 11(2):119-26. PubMed ID: 11912359
[TBL] [Abstract][Full Text] [Related]
19. Distribution of brimonidine into anterior and posterior tissues of monkey, rabbit, and rat eyes.
Acheampong AA; Shackleton M; John B; Burke J; Wheeler L; Tang-Liu D
Drug Metab Dispos; 2002 Apr; 30(4):421-9. PubMed ID: 11901096
[TBL] [Abstract][Full Text] [Related]
20. Ongoing clinical assessment of the safety profile and efficacy of brimonidine compared with timolol: year-three results. Brimonidine Study Group II.
Melamed S; David R
Clin Ther; 2000 Jan; 22(1):103-11. PubMed ID: 10688394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
